Facilities
- History & Future
- Vaccinogen Timeline
- Chairman's Letter
- What is OncoVAX®?
- Driving Principles
- Management
- Board of Directors
- Facilities
- Publications
The Emmen Manufacturing Facility
Vaccinogen has a licensed and validated current Good Manufacturing Practices (cGMP) certified plant in Emmen, The Netherlands for the manufacture of OncoVAX®. The Dutch National Institute of Public Health and Environmental Protection (“RIVM”) has approved Vaccinogen’s sterile vaccine manufacturing process, and the Dutch Ministry of Health, Welfare and Sport (“VWS”) has licensed the manufacturing facility. This 900-m² (9600 ft²) facility has five class C manufacturing suites and two class B quality control laboratories with a capacity to produce 3,500 OncoVAX® vaccines per year ($130M/£65M) – a production amount sufficient to cover the pivotal Phase IIIb clinical trial and the commercial sales of OncoVAX® in Switzerland and Eastern Europe.